- Mineralys reported Items 1.01 and 1.02 regarding its license agreement with Tanabe Pharma for lorundrostat.
- Filing indicates modification or termination of core license terms, creating strategic uncertainty.
?? Negative AI Sentiment (-2.0 / 10)
Single signal · #45278
$MLYS — AI Filing Signal
Public delayed archive entry for this Stock Catalyst AI alert.